Improving the Treatment Outcome of Patients with Chronic Lymphocytic Leukemia Through Targeted Antibody Therapy

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 303-327

  Stephens, Deborah M ^a   Byrd, John C ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Antibody; Chemoimmunotherapy; Chronic lymphocytic leukemia; Immunotherapy; Monoclonal antibody

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; AZERRA; BENDAMUSTINE; CARBOPLATIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACETUZUMAB; ETOPOSIDE; FLUDARABINE; HUMAX CD 20; IBRUTINIB; IDELALISIB; IFOSFAMIDE; IMGN 529; IMMU 114; LENALIDOMIDE; LUCATUMUMAB; MDX 1342; METHYLPREDNISOLONE; OBINUTUZUMAB; OFATUMUMAB; PENTOSTATIN; PLACEBO; RITUXIMAB; TRU 016; UNCLASSIFIED DRUG; VELTUZUMAB; XMAB 5574;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; AMINO ACID SUBSTITUTION; ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ASEPTIC MENINGITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL PHAGOCYTOSIS; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOGENETICS; CYTOPENIA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEALTH CARE QUALITY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; LARGE CELL LYMPHOMA; LIPID RAFT; LOW DRUG DOSE; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; UREMIA; URTICARIA;

EID: 84875762455     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.12.003     Document Type: Review

References (130)

1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), SEER stat fact sheet: chronic lymphocytic lymphoma. Based on November 2011 SEER data submission, posted to the SEER web site. 2012. Available at: . Accessed June 1, 2012. http://seer.cancer.gov/statfacts/html/clyl.html.
2. Zenz T., Mertens D., Kuppers R., et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010, 10(1):37-50.
3. Scott A.M., Allison J.P., Wolchok J.D. Monoclonal antibodies in cancer therapy. Cancer Immun 2012, 12:14.
4. Stashenko P., Nadler L.M., Hardy R., et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980, 125(4):1678-1685.
5. Press O.W., Howell-Clark J., Anderson S., et al. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994, 83(5):1390-1397.
6. Li H., Ayer L.M., Lytton J., et al. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003, 278(43):42427-42434.
7. Uchida J., Lee Y., Hasegawa M., et al. Mouse CD20 expression and function. Int Immunol 2004, 16(1):119-129.
8. Cragg M.S., Morgan S.M., Chan H.T., et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101(3):1045-1052.
9. Simons K., Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002, 110(5):597-603.
10. Ivanov A., Beers S.A., Walshe C.A., et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009, 119(8):2143-2159.
11. Byrd J.C., Kitada S., Flinn I.W., et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99(3):1038-1043.
12. Beum P.V., Kennedy A.D., Williams M.E., et al. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176(4):2600-2609.
13. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
14. Farag S.S., Flinn I.W., Modali R., et al. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004, 103(4):1472-1474.
15. Anand M., Chodda S.K., Parikh P.M., et al. Dysregulated cytokine production by monocytes from chronic lymphocytic leukemia patients. Cancer Biother Radiopharm 1998, 13(1):43-48.
16. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16(8):2825-2833.
17. Jaglowski S.M., Byrd J.C. Rituximab in chronic lymphocytic leukemia. Semin Hematol 2010, 47(2):156-169.
18. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51(5):364-369.
19. Ziegler H.W., Kay N.E., Zarling J.M. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 1981, 27(3):321-327.
20. Kay N.E., Zarling J.M. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984, 63(2):305-309.
21. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998, 9(9):995-1001.
22. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19(8):2153-2164.
23. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19(8):2165-2170.
24. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003, 21(9):1746-1751.
25. Schulz H., Klein S.K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002, 100(9):3115-3120.
26. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101(1):6-14.
27. Byrd J.C., Gribben J.G., Peterson B.L., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24(3):437-443.
28. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105(1):49-53.
29. Woyach J.A., Ruppert A.S., Heerema N.A., et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011, 29(10):1349-1355.
30. Del Poeta G., Del Principe M.I., Consalvo M.A., et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 2005, 104(12):2743-2752.
31. Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112(4):975-980.
32. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23(18):4070-4078.
33. Tsimberidou A.M., Tam C., Abruzzo L.V., et al. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009, 115(2):373-380.
34. Lin K.I., Tam C.S., Keating M.J., et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009, 113(14):3168-3171.
35. Lamanna N., Kalaycio M., Maslak P., et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006, 24(10):1575-1581.
36. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109(2):405-411.
37. Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30(26):3209-3216.
38. Fischer K., Stilgenbauer S., Schweighofer C.D., et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2008, 112(11):330. [abstracts].
39. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
40. Robak T., Dmoszynska A., Solal-Celigny P., et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1756-1765.
41. Wu L., Adams M., Carter T., et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14(14):4650-4657.
42. Badoux X.C., Keating M.J., O'Brien S., et al. Final analysis of a phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2011, 118(21):980. [abstracts].
43. James D.F., Brown J.R., Werner L., et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia (CLL) a multicenter study of the CLL research consortium. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):291. [abstracts].
44. Del Poeta G., Del Principe M.I., Buccisano F., et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008, 112(1):119-128.
45. Zecca M., De Stefano P., Nobili B., et al. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001, 97(12):3995-3997.
46. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002, 99(3):1092-1094.
47. Gupta N., Kavuru S., Patel D., et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002, 16(10):2092-2095.
48. D'Arena G., Laurenti L., Capalbo S., et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006, 81(8):598-602.
49. Hegde U.P., Wilson W.H., White T., et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002, 100(6):2260-2262.
50. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15(10):3266-3274.
51. Byrd J.C., Waselenko J.K., Maneatis T.J., et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999, 17(3):791-795.
52. Dervite I., Hober D., Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001, 344(1):68-69.
53. Carson K.R., Focosi D., Major E.O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009, 10(8):816-824.
54. Teeling J.L., Mackus W.J., Wiegman L.J., et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177(1):362-371.
55. Teeling J.L., French R.R., Cragg M.S., et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104(6):1793-1800.
56. Pawluczkowycz A.W., Beurskens F.J., Beum P.V., et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009, 183(1):749-758.
57. Coiffier B., Lepretre S., Pedersen L.M., et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008, 111(3):1094-1100.
58. Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010, 28(10):1749-1755.
59. Wierda W.G., Padmanabhan S., Chan G.W., et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011, 118(19):5126-5129.
60. Flinn I.W., Harwin W.N., Macias-Perez I.M., et al. A phase II trial of ofatumumab for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):3912. [abstracts].
61. Wierda W.G., Kipps T.J., Durig J., et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117(24):6450-6458.
62. Falchi L., Keating M.J., Badoux X.C., et al. Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). J Clin Onc (ASCO Annual Meeting Abstracts) 2012, 30(15 Suppl):6516. [abstracts].
63. Shanafelt T.D., Lanasa M.C., Zent C.S., et al. Ofatumumab based chemoimmunotherapy (CIT) for patients with previously untreated CLL. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):3898. [abstracts].
64. Teichman M.L., Ho V.Q., Balducci L., et al. Efficacy of ofatumumab and high-dose methylprednisolone for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2011, 118(21):4619. [abstracts].
65. Ujjani C.S., Gehan E.A., Ramzi P., et al. Ofatumumab and bendamustine in previously treated CLL and SLL. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):4615. [abstracts].
66. Jaglowski S.M., Jones J.A., Flynn J.M., et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Onc (ASCO Annual Meeting Abstracts) 2012, 30(15 Suppl):6508. [abstracts].
67. Furman R.R., Barrientos J.C., Sharman J.P., et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3K{delta}) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL). J Clin Onc (ASCO Annual Meeting Abstracts) 2012, 30(15 Suppl):6518. [abstracts].
68. Ferrara C., Stuart F., Sondermann P., et al. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006, 281(8):5032-5036.
69. Alduaij W., Ivanov A., Honeychurch J., et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011, 117(17):4519-4529.
70. Laurenti L., De Padua L., D'Arena G., et al. New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Mini Rev Med Chem 2011, 11(6):508-518.
71. Niederfellner G.J., Lammens A., Schwaiger M., et al. Crystal structure analysis reveals that the novel type ii anti-CD20 antibody GA101 interacts with a similar epitope as rituximab and ocrelizumab but in a fundamentally different way. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):3726. [abstracts].
72. Zenz T., Volden M., Mast T., et al. In vitro activity of the Type II anti-CD20 antibody GA101 in refractory, genetic high-risk CLL. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):2379. [abstracts].
73. Patz M., Forcob N., Muller B., et al. Depletion of chronic lymphocytic leukemia cells from whole blood samples mediated by the anti-CD20 antibodies rituximab and GA101. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):2365. [abstracts].
74. Mossner E., Brunker P., Moser S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115(22):4393-4402.
75. Dalle S., Reslan L., Besseyre de Horts T., et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011, 10(1):178-185.
76. Salles G., Morschhauser F., Lamy T., et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012, 119(22):5126-5132.
77. Morschhauser F., Cartron G., Lamy T., et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):884. [abstracts].
78. Cartron G., Morschhauser F., Thieblemont C., et al. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(2 Suppl):39-40. [abstract 0101].
79. Sehn L.H., Assouline S.E., Stewart D.A., et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012, 119(22):5118-5125.
80. Goldenberg D.M., Rossi E.A., Stein R., et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009, 113(5):1062-1070.
81. Negrea O.G., Allen S.L., Rai K.R., et al. Subcutaneous injections of low doses of humanized anti-cd20 veltuzumab for treatment of indolent B-cell malignancies. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):3757. [abstracts].
82. Jain N., Wierda W., Ferrajoli A., et al. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 2009, 115(19):4533-4539.
83. 131I-tositumomab in clinical practice. J Nucl Med 2007, 48(11):1767-1776.
84. Robak T., Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011, 25(1):13-25.
85. Rossmann E.D., Lundin J., Lenkei R., et al. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001, 2(5):300-306.
86. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998, 22(2):185-191.
87. Crowe J.S., Hall V.S., Smith M.A., et al. Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material. Clin Exp Immunol 1992, 87(1):105-110.
88. Hale G., Clark M., Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985, 134(5):3056-3061.
89. Mone A.P., Cheney C., Banks A.L., et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 2006, 20(2):272-279.
90. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103(9):3278-3281.
91. Stilgenbauer S., Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002, 347(6):452-453.
92. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99(10):3554-3561.
93. Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2009, 27(24):3994-4001.
94. Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25(35):5616-5623.
95. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004, 18(6):1093-1101.
96. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98(12):2657-2663.
97. Byrd J.C., Peterson B.L., Rai K.R., et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 2009, 50(10):1589-1596.
98. Lin T.S., Donohue K.A., Byrd J.C., et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010, 28(29):4500-4506.
99. Hainsworth J.D., Vazquez E.R., Spigel D.R., et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008, 112(6):1288-1295.
100. Horejsi V., Vlcek C. Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63. FEBS Lett 1991, 288(1-2):1-4.
101. Wright M.D., Tomlinson M.G. The ins and outs of the transmembrane 4 superfamily. Immunol Today 1994, 15(12):588-594.
102. Schwartz-Albiez R., Dorken B., Hofmann W., et al. The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J Immunol 1988, 140(3):905-914.
103. van Spriel A.B., Puls K.L., Sofi M., et al. A regulatory role for CD37 in T cell proliferation. J Immunol 2004, 172(5):2953-2961.
104. Zhao X., Lapalombella R., Joshi T., et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007, 110(7):2569-2577.
105. Lapalombella R., Yeh Y.Y., Wang L., et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 2012, 21(5):694-708.
106. Furman R.R., Andritsos L., Flinn I.W., et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. Blood (ASH Annual Meeting Abstracts) 2010, 116(21):56. [abstracts].
107. Awan F.T., Pagel J.M., Andritsos L.A., et al. Phase 1 study of Tru-016, an anti-CD37 SMIP™ protein in naive and relapsed and/or refractory CLL patients. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):1792. [abstracts].
108. Krause G., Patz M., Isaeva P., et al. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 2012, 26(3):546-549.
109. Deckert J., Chicklas S., Yi Y., et al. Potent B-cell depletion by IMGN529, a CD37-targeting antibody-maytansinoid conjugate for the treatment of B-Cell malignancies. Blood (ASH Annual Meeting Abstracts) 2011, 118(21):3726. [abstracts].
110. Law C.L., Gordon K.A., Collier J., et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005, 65(18):8331-8338.
111. Damle R.N., Ghiotto F., Valetto A., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99(11):4087-4093.
112. Clayton E., Bardi G., Bell S.E., et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002, 196(6):753-763.
113. Cuni S., Perez-Aciego P., Perez-Chacon G., et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18(8):1391-1400.
114. Furman R.R., Asgary Z., Mascarenhas J.O., et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164(4):2200-2206.
115. Romano M.F., Lamberti A., Tassone P., et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998, 92(3):990-995.
116. Lapalombella R., Gowda A., Joshi T., et al. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br J Haematol 2009, 144(6):848-855.
117. Furman R.R., Forero-Torres A., Shustov A., et al. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010, 51(2):228-235.
118. Andritsos L.A., Johnson A.J., Lozanski G., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008, 26(15):2519-2525.
119. Luqman M., Klabunde S., Lin K., et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008, 112(3):711-720.
120. Byrd J.C., Kipps T.J., Flinn I.W., et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53(11):2136-2142.
121. Fujimoto M., Poe J.C., Hasegawa M., et al. CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol Res 2000, 22(2-3):281-298.
122. Horton H.M., Bernett M.J., Pong E., et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008, 68(19):8049-8057.
123. Awan F.T., Lapalombella R., Trotta R., et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010, 115(6):1204-1213.
124. Zalevsky J., Leung I.W., Karki S., et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113(16):3735-3743.
125. Cardarelli P.M., Rao-Naik C., Chen S., et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother 2010, 59(2):257-265.
126. Camacho L.H., Joyce R., Brown J.R., et al. A phase 1, open-label, multi-center, multiple-dose, dose-escalation study of MDX-1342 in patients with CD19-positive refractory/relapsed chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts) 2009, 114(22):3425. [abstracts].
127. Stein R., Gupta P., Chen X., et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood 2010, 115(25):5180-5190.
128. Mone A.P., Huang P., Pelicano H., et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004, 103(5):1846-1854.
129. Stein R., Qu Z., Chen S., et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006, 108(8):2736-2744.
130. Lin T.S., Stock W., Xu H., et al. A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma 2009, 50(12):1958-1963.